H19 and metabolic dysfunction-associated steatohepatitis: Mice with nonalcoholic steatohepatitis that were treated with 50 mg/kg BER for 9 weeks showed down-regulated H19, high antioxidant levels, low lipid and glucose profiles and low inflammatory markers, indicating that BER decreased inflammation by preventing activation of Kupffer cells characterized by high ARG1, inhibiting hepatic stellate cell activation by inhibiting H19 and increasing insulin sensitivity by reducing IGF2 [42].